Literature DB >> 15598469

The hypoxia-inducible factor and tumor progression along the angiogenic pathway.

M Christiane Brahimi-Horn1, Jacques Pouysségur.   

Abstract

The hypoxia-inducible factor (HIF) is a transcription factor that plays a key role in the response of cells to oxygen levels. HIF is a heterodimer of alpha- and beta-subunits where the alpha-subunit is translated constitutively but has a very short half-life under normal oxygen concentrations. Negative regulation of the half-life and activity of the alpha-subunit is dependent on its posttranslational hydroxylation by hydroxylases that are dependent on oxygen for activity. Thus under low oxygen (hypoxic) conditions the hydroxylases are inactive and the alpha-subunit is stable and able to interact with the beta-subunit to bind and induce transcription of target genes. Hypoxic conditions are encountered in development and in disease states such as cancer. Tumors that have outstripped their blood supply become hypoxic and express high levels of HIF. HIF in turn targets genes that induce survival, glycolysis, and angiogenesis, a form of neovascularization, which ensures the tumor with a continued supply of oxygen and nutrients for further growth.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15598469     DOI: 10.1016/S0074-7696(04)42004-X

Source DB:  PubMed          Journal:  Int Rev Cytol        ISSN: 0074-7696


  20 in total

Review 1.  Lung cancer therapeutics that target signaling pathways: an update.

Authors:  M Roshni Ray; David Jablons; Biao He
Journal:  Expert Rev Respir Med       Date:  2010-10       Impact factor: 3.772

Review 2.  Cancer nanomedicines targeting tumor extracellular pH.

Authors:  Li Tian; You Han Bae
Journal:  Colloids Surf B Biointerfaces       Date:  2011-10-25       Impact factor: 5.268

3.  Overexpression of Tie2 is associated with poor prognosis in patients with gastric cancer.

Authors:  Wei-Jun Yang; Ying-Xue Hao; Xia Yang; Xiao-Lan Fu; Yan Shi; Hai-Ling Yue; Peng Yin; Hao-Lin Dong; Pei-Wu Yu
Journal:  Oncol Lett       Date:  2018-03-23       Impact factor: 2.967

4.  Suppression of hypoxia-induced HIF-1alpha and of angiogenesis in endothelial cells by myo-inositol trispyrophosphate-treated erythrocytes.

Authors:  Claudine Kieda; Ruth Greferath; Claire Crola da Silva; Konstantina C Fylaktakidou; Jean-Marie Lehn; Claude Nicolau
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-06       Impact factor: 11.205

Review 5.  Dietary hyperglycemia, glycemic index and metabolic retinal diseases.

Authors:  Chung-Jung Chiu; Allen Taylor
Journal:  Prog Retin Eye Res       Date:  2010-09-22       Impact factor: 21.198

6.  Interaction between HIF-1 alpha (ODD) and hARD1 does not induce acetylation and destabilization of HIF-1 alpha.

Authors:  Thomas Arnesen; Xianguo Kong; Rune Evjenth; Darina Gromyko; Jan Erik Varhaug; Zhao Lin; Nianli Sang; Jaime Caro; Johan R Lillehaug
Journal:  FEBS Lett       Date:  2005-11-02       Impact factor: 4.124

Review 7.  Hypoxia and cancer.

Authors:  M Christiane Brahimi-Horn; Johanna Chiche; Jacques Pouysségur
Journal:  J Mol Med (Berl)       Date:  2007-11-20       Impact factor: 4.599

8.  Osteogenic differentiation of adipose-derived stem cells is hypoxia-inducible factor-1 independent.

Authors:  Suchit Sahai; Amanda Williams; Matthew L Skiles; James O Blanchette
Journal:  Tissue Eng Part A       Date:  2013-04-04       Impact factor: 3.845

Review 9.  Targeting tumor angiogenesis with histone deacetylase inhibitors.

Authors:  Leigh Ellis; Hans Hammers; Roberto Pili
Journal:  Cancer Lett       Date:  2008-12-25       Impact factor: 8.679

10.  Hypoxia skews dendritic cells to a T helper type 2-stimulating phenotype and promotes tumour cell migration by dendritic cell-derived osteopontin.

Authors:  Meixiang Yang; Chunhong Ma; Shuxun Liu; Jintang Sun; Qianqian Shao; Wenjuan Gao; Yan Zhang; Zewu Li; Qi Xie; Zhaogang Dong; Xun Qu
Journal:  Immunology       Date:  2008-10-21       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.